DOI QR코드

DOI QR Code

Tanshinone IIA Reverses the Malignant Phenotype of SGC7901 Gastric Cancer Cells

  • Published : 2013.01.31

Abstract

Backgrounds: Tanshinone IIA (TIIA), a phenanthrenequinone derivative extracted from Salvia miltiorrhiza BUNGE, has been reported to be a natural anti-cancer agent in a variety of tumor cells. However, the effect of TIIA on gastric cancer cells remains unknown. In the present study, we investigated the influence of TIIA on the malignant phenotype of SGC7901 gastric cancer cells. Methods: Cells cultured in vitro were treated with TIIA (0, 1, 5, $10{\mu}g/ml$) and after incubation for different periods, cell proliferation was measured by MTT method and cell apoptosis and cell cycling were assessed by flow cytometry (FCM). The sensitivity of SGC7901 gastric cancer cells to anticancer chemotherapy was investigated with the MTT method, while cell migration and invasion were examined by wound-healing and transwell assays, respectively. Results: TIIA (1, 5, $10{\mu}g/ml$) exerted powerful inhibitory effects on cell proliferation (P < 0.05, and P < 0.01), and this effect was time- and dose-dependent. FCM results showed that TIIA induced apoptosis of SGC7901 cells, reduced the number of cells in S phase and increased those in G0/G1 phase. TIIA also significantly increased the sensitivity of SGC7901 gastric cancer cells to ADR and Fu. Moreover, wound-healing and transwell assays showed that TIIA markedly decreased migratory and invasive abilities of SGC7901 cells. Conclusions: TIIA can reverse the malignant phenotype of SGC7901 gastric cancer cells, indicating that it may be a promising therapeutic agent.

Acknowledgement

Supported by : National Natural Science Foundation of China

References

  1. Zhou L, Zuo Z and Chow MS (2005). Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol, 45, 1345-59. https://doi.org/10.1177/0091270005282630
  2. Zhou LH, Hu Q, Sui H, et al (2012). Tanshinone II-A Inhibits Angiogenesis through Down Regulation of COX-2 in Human Colorectal Cancer. Asian Pac J Cancer Prev, 13, 4453-8. https://doi.org/10.7314/APJCP.2012.13.9.4453
  3. Pan TL, Hung YC, Wang PW, et al (2010). Functional proteomic and structural insights into molecular targets related to the growth inhibitory effect of tanshinone IIA on HeLa cells. Proteomics, 10, 914-29.
  4. Parkin DM (2004). International variation. Oncogene, 23, 6329-40. https://doi.org/10.1038/sj.onc.1207726
  5. Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
  6. Parkin DM, Bray FI and Devesa SS (2001). Cancer burden in the year 2000. The global picture. Eur J Cancer, 37, S4-66.
  7. Shi WT, Wei L, Xiang J, et al (2012). Chinese patients with gastric cancer need targeted adjuvant chemotherapy schemes. Asian Pac J Cancer Prev, 13, 5263-72. https://doi.org/10.7314/APJCP.2012.13.10.5263
  8. Su CC, Chen GW, Kang JC, et al (2008). Growth inhibition and apoptosis induction by tanshinone IIA in human colon adenocarcinoma cells. Planta Med, 74, 1357-62. https://doi.org/10.1055/s-2008-1081299
  9. Su CC, Lin YH (2008). Tanshinone IIA inhibits human breast cancer cells through increased Bax to Bcl-xL ratios. Int J Mol Med, 22, 357-61.
  10. Wang AM, Sha SH, Lesniak W, et al (2003). Tanshinone (Salviae miltiorrhizae extract) preparations attenuate aminoglycosideinduced free radical formation in vitro and ototoxicity in vivo. Antimicrob Agents Chemother, 47, 1836-41. https://doi.org/10.1128/AAC.47.6.1836-1841.2003
  11. Werner M, Becker KF, Keller G, et al (2001). Gastric adenocarcinoma: pathomorphology and molecular pathology. J Cancer Res Clin Oncol, 127, 207-16. https://doi.org/10.1007/s004320000195
  12. Won SH, Lee HJ, Jeong SJ, et al (2010). Tanshinone IIA induces mitochondria dependent apoptosis in prostate cancer cells in association with an inhibition of phosphoinositide 3-kinase/AKT pathway. Biol Pharm Bull, 33, 1828-34. https://doi.org/10.1248/bpb.33.1828
  13. Wu MS, Shun CT, Wang HP, et al (1997). Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection. Gastroenterology, 112, 1457-65. https://doi.org/10.1016/S0016-5085(97)70071-4
  14. Yang LJ, Jeng CJ, Kung HN, et al (2005). Tanshinone IIA isolated from Salvia miltiorrhiza elicits the cell death of human endothelial cells. J Biomed Sci, 12, 347-61. https://doi.org/10.1007/s11373-005-0973-z
  15. Yang R, Liu A, Ma X, et al (2008). Sodium tanshinone IIA sulfonate protects cardiomyocytes against oxidative stressmediated apoptosis through inhibiting JNK activation. J Cardiovasc Pharmacol, 51, 396-401. https://doi.org/10.1097/FJC.0b013e3181671439
  16. Yasui W, Yokozaki H, Fujimoto J, et al (2000). Genetic and epigenetic alterations in multistep carcinogenesis of the stomach. J Gastroenterol, 35, 111-5.
  17. Yuan SL, Wei YQ, Wang XJ, et al (2004). Growth inhibition and apoptosis induction of tanshinone II-A on human hepatocellular carcinoma cells. World J Gastroenterol, 10, 2024-8.
  18. Yuxian X, Feng T, Ren L, et al (2009). Tanshinone II-A inhibits invasion and metastasis of human hepatocellular carcinoma cells in vitro and in vivo. Tumori, 95, 789-95.
  19. Zhang K, Li J, Meng W, et al (2010). C/EBPbeta and CHOP participate in tanshinone IIA-induced differentiation and apoptosis of acute promyelocytic leukemia cells in vitro. Int J Hematol, 92, 571-8. https://doi.org/10.1007/s12185-010-0686-6
  20. Alberts SR, Cervantes A, van de Velde CJ (2003). Gastric cancer: epidemiology, pathology and treatment. Ann Oncol, 14, i31-6.
  21. Choi HS, Cho DI, Choi HK, et al (2004). Molecular mechanisms of inhibitory activities of tanshinones on lipopolysaccharideinduced nitric oxide generation in RAW 264.7 cells. Arch Pharm Res, 27, 1233-7. https://doi.org/10.1007/BF02975887
  22. Correa P (1992). Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res, 52, 6735-40.
  23. Fu J, Huang H, Liu J, et al (2007). Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. Eur J Pharmacol, 568, 213-21. https://doi.org/10.1016/j.ejphar.2007.04.031
  24. Gao J, Yang G, Pi R, et al (2008). Tanshinone IIA protects neonatal rat cardiomyocytes from adriamycin-induced apoptosis. Transl Res, 151, 79-87. https://doi.org/10.1016/j.trsl.2007.11.005
  25. Huang JY, Xu YY, Sun Z, et al (2012). Comparison Different Methods of Intraoperative and Intraperitoneal Chemotherapy for Patients with Gastric Cancer: A Meta-analysis. Asian Pac J Cancer Prev, 13, 4379-85. https://doi.org/10.7314/APJCP.2012.13.9.4379
  26. IARC (2004). Globocan 2002: Cancer Incidence, Mortality and Prevalence Worldwide, version 2.0. In IARC Cancer Base no. 5, Eds Ferlay J, Bray F, Pisani P, et al. IARC Press, Lyon, France.
  27. Jiao JW, Wen F (2011). Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells. Oncol Rep, 25, 781-8.
  28. Lam BY, Lo AC, Sun X, et al (2003). Neuroprotective effects of tanshinones in transient focal cerebral ischemia in mice. Phytomedicine, 10, 286-91. https://doi.org/10.1078/094471103322004776
  29. Li L, Ying XJ, Sun TT, et al (2012). Overview of methodological quality of systematic reviews about gastric cancer risk and protective factors. Asian Pac J Cancer Prev, 13, 2069-79. https://doi.org/10.7314/APJCP.2012.13.5.2069
  30. Liotta LA, Stetler-Stevenson WG (1991). Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res, 51, 5054s-9s.
  31. Liu JJ, Lin DJ, Liu PQ, et al (2006). Induction of apoptosis and inhibition of cell adhesive and invasive effects by tanshinone IIA in acute promyelocytic leukemia cells in vitro. J Biomed Sci, 13, 813-23. https://doi.org/10.1007/s11373-006-9110-x
  32. Lochhead P, El-Omar EM (2008). Gastric cancer. Br Med Bull, 85, 87-100. https://doi.org/10.1093/bmb/ldn007
  33. Lu Q, Zhang P, Zhang X, et al (2009). Experimental study of the anti-cancer mechanism of tanshinone IIA against human breast cancer. Int J Mol Med, 24, 773-80.

Cited by

  1. Tanshinone IIA blocks epithelial-mesenchymal transition through HIF-1α downregulation, reversing hypoxia-induced chemotherapy resistance in breast cancer cell lines vol.31, pp.6, 2014, https://doi.org/10.3892/or.2014.3140
  2. Tanshinone IIA inhibits human gastric carcinoma AGS cell growth by decreasing BiP, TCTP, Mcl-1 and Bcl-xL and increasing Bax and CHOP protein expression vol.34, pp.6, 2014, https://doi.org/10.3892/ijmm.2014.1949
  3. Cryptotanshinone inhibits lung tumorigenesis and induces apoptosis in cancer cells in vitro and in vivo vol.9, pp.6, 2014, https://doi.org/10.3892/mmr.2014.2093
  4. Tanshinone IIA decreases the migratory ability of AGS cells by decreasing the protein expression of matrix metalloproteinases, nuclear factor κB-p65 and cyclooxygenase-2 vol.13, pp.2, 2015, https://doi.org/10.3892/mmr.2015.4658
  5. Tanshinone IIA decreases the protein expression of EGFR, and IGFR blocking the PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells both in vitro and in vivo vol.36, pp.2, 2016, https://doi.org/10.3892/or.2016.4857
  6. Tanshinone I induces apoptosis and pro-survival autophagy in gastric cancers vol.77, pp.6, 2016, https://doi.org/10.1007/s00280-016-3034-6
  7. Tanshinone IIA suppresses gastric cancer cell proliferation and migration by downregulation of FOXM1 vol.37, pp.3, 2017, https://doi.org/10.3892/or.2017.5408